HC Wainwright Reaffirms Buy Rating for OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 413.76% from the stock’s previous close.

OKYO Pharma Stock Performance

OKYO stock opened at $1.36 on Monday. OKYO Pharma has a 1-year low of $0.81 and a 1-year high of $1.74. The business has a 50 day simple moving average of $1.31 and a two-hundred day simple moving average of $1.16.

Institutional Trading of OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. FNY Investment Advisers LLC bought a new stake in shares of OKYO Pharma Limited (NASDAQ:OKYO) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $25,000. FNY Investment Advisers LLC owned 0.06% of OKYO Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.